Kayothera, Inc. Raises $8 Million In Series A Financing Led By Accelerator Life Science Partners To Develop Novel Cancer Immunotherapeutics
Kayothera, Inc. Raises $8 Million In Series A Financing Led By Accelerator Life Science Partners To Develop Novel Cancer Immunotherapeutics
03/16/22, 1:00 PM
Location
seattleMoney raised
$8 million
Round Type
series a
KayoThera, Inc. (“KayoThera”), an early-stage therapeutics company developing novel cancer immunotherapies, today announces the closing of an $8 million Series A round of financing. The financing was led by Accelerator Life Science Partners (“ALSP”) with participation from BioAdvance and 7G Bioventures. KayoThera will focus its therapeutic development efforts on its lead oncology program to further advance the technology towards a product that will benefit patients with late-stage and metastatic cancers.
Company Info
Location
seattle, washington, united states
Additional Info
KayoThera, Inc. is an early-stage therapeutics company focused on the development of a new class of cancer immunotherapeutics. KayoThera is developing therapies to treat late-stage and metastatic cancers including breast, lung, pancreatic, colorectal, brain, and kidney cancers. Based on discoveries from Dr. Mark Esposito’s post-doctoral research in Princeton University and professor Yibin Kang, PhD. The company was initially funded by Foundation Venture Capital Group (FVCG). For more information, visit www.kayothera.com.